Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001615774-17-004219
Filing Date
2017-08-10
Accepted
2017-08-10 15:20:36
Documents
55
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q s107089_10q.htm 10-Q 371493
2 EXHIBIT 31.1 s107089_ex31-1.htm EX-31.1 16972
3 EXHIBIT 32.1 s107089_ex32-1.htm EX-32.1 7059
  Complete submission text file 0001615774-17-004219.txt   3277414

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE bthe-20170630.xml EX-101.INS 633065
5 XBRL SCHEMA FILE bthe-20170630.xsd EX-101.SCH 33887
6 XBRL CALCULATION FILE bthe-20170630_cal.xml EX-101.CAL 46639
7 XBRL DEFINITION FILE bthe-20170630_def.xml EX-101.DEF 153642
8 XBRL LABEL FILE bthe-20170630_lab.xml EX-101.LAB 298385
9 XBRL PRESENTATION FILE bthe-20170630_pre.xml EX-101.PRE 231870
Mailing Address 354 MERRIMACK STREET #4 LAWRENCE MA 01843
Business Address 354 MERRIMACK STREET #4 LAWRENCE MA 01843 (603) 935-9799
Boston Therapeutics, Inc. (Filer) CIK: 0001473579 (see all company filings)

EIN.: 270801073 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-54586 | Film No.: 171021217
SIC: 2834 Pharmaceutical Preparations